Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Director, Commercial Training
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Director, Commercial Training
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and an inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL ...
Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and an inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
Quick apply
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and an inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL ...
Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and an inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
... the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive ... molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for ...
Kinase Inhibitor information
See salary details
$33K - $38.7K
5% of jobs
$38.7K - $44.4K
10% of jobs
$44.4K - $50K
7% of jobs
$51.1K is the 25th percentile. Wages below this are outliers.
$50K - $55.7K
15% of jobs
$55.7K - $61.4K
7% of jobs
The median wage is $63.4K / yr.
$61.4K - $67.1K
15% of jobs
$67.1K - $72.8K
11% of jobs
$77K is the 75th percentile. Wages above this are outliers.
$72.8K - $78.5K
6% of jobs
$78.5K - $84.1K
14% of jobs
$84.1K - $89.8K
7% of jobs
$89.8K - $95.5K
2% of jobs
$33K
$65K
$95.5K
How much do kinase inhibitor jobs pay per year?
What are the key skills and qualifications needed to thrive as a Kinase Inhibitor researcher, and why are they important?
What are kinase inhibitors?
What are some common challenges faced by professionals working on kinase inhibitor research and development?
What is the difference between Kinase Inhibitor vs Pharmacologist?
| Aspect | Kinase Inhibitor | Pharmacologist |
|---|---|---|
| Required Credentials | Typically a PhD or PharmD in biochemistry, molecular biology, or related fields | PhD in pharmacology, biochemistry, or related disciplines |
| Work Environment | Laboratories, biotech or pharmaceutical companies, research institutions | Research labs, academia, pharmaceutical companies, regulatory agencies |
| Industry Usage | Drug development, cancer research, targeted therapy development | Drug testing, safety evaluation, pharmacokinetics, and pharmacodynamics studies |
While both roles require advanced degrees and involve research, Kinase Inhibitors are specialized in developing and testing specific enzyme inhibitors for therapeutic use, whereas Pharmacologists focus broadly on drug effects, mechanisms, and safety. Kinase Inhibitors are more product-focused within drug development, while Pharmacologists often work in broader pharmacological research and regulation.

Full-time
This job post has expired today. Applications are no longer accepted.
Job description
We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation - TRUE Innovation!
Position Summary:
The Senior Director, Pricing & Contracting is responsible for developing and leading the U.S. pricing and contracting strategy to support optimal market access, reimbursement, and financial performance for Zenas BioPharma's portfolio, including development of contracting strategies with national/regional payer organizations, PBMs, and government payer segments. Reporting to the Vice President, U.S. Market Access, this role will lead the development of pricing strategy, gross-to-net modeling, and payer contracting strategies that support both product launch planning and lifecycle management.
The Senior Director will play a key role in establishing launch pricing strategy while also overseeing ongoing pricing governance, access financial modeling, and contracting frameworks with payer organizations, pharmacy benefit managers (PBMs), and other healthcare stakeholders. This individual will work closely with the Payer Strategy team to support contract negotiations and ensure pricing and contracting decisions align with overall market access strategy and company financial objectives.
This role will collaborate cross-functionally with Finance, Market Access, Legal, Compliance, Medical Affairs, and Commercial leadership to evaluate pricing scenarios, inform access strategy decisions, and support the successful commercialization of Zenas therapies.
This role offers a unique opportunity to shape pricing and contracting strategy in preparation for upcoming product launches while supporting long-term access and financial performance for the Zenas portfolio.
Key Responsibilities:
- Lead the development and execution of U.S. pricing strategy, including launch price recommendations and lifecycle pricing management for Zenas BioPharma's portfolio.
- Develop and manage gross-to-net (GTN) models that support financial forecasting, access strategy decisions, and pricing scenario planning.
- Design and implement payer contracting strategies, including rebate structures and contracting frameworks with pharmacy benefit managers (PBMs), national payer organizations, and regional health plans.
- Partner with the Payer Strategy team to support contract negotiations and ensure pricing and rebate strategies align with payer coverage objectives.
- Lead financial modeling and pricing scenario analyses to evaluate the impact of pricing and contracting strategies on market access, reimbursement, and overall company financial performance.
- Collaborate closely with Finance to ensure pricing assumptions, GTN forecasts, and contracting scenarios are accurately reflected in financial planning and forecasting models.
- Monitor competitive pricing dynamics, payer contracting trends, and reimbursement environments to inform pricing strategy and market access planning.
- Support the development of pricing governance processes and provide strategic recommendations to senior leadership regarding pricing decisions and contracting strategies.
- Provide strategic pricing insights to support launch planning, payer engagement strategy, and long-term market access objectives.
- Provide strategic oversight of government pricing considerations, including AMP, Best Price, Medicaid rebate implications, and 340B pricing impacts, ensuring pricing and contracting strategies align with regulatory requirements.
- Partner with Legal and Compliance to ensure pricing and contracting practices adhere to regulatory requirements and company compliance standards.
- Collaborate cross-functionally with Market Access, Commercial, Medical Affairs, HEOR, and Finance teams to ensure alignment between pricing strategy, access strategy, and commercial objectives.
- Support the evaluation of pricing and contracting strategies across different payer segments, including commercial and government payer environments
Qualifications:
- Minimum of 12+ years of experience in the pharmaceutical or biotechnology industry, including at least 7+ years in Pricing, Contracting, Market Access, or Managed Markets roles.
- Demonstrated experience developing U.S. pricing strategy, including launch pricing recommendations and lifecycle pricing management for specialty or rare disease therapies.
- Proven experience developing and managing gross-to-net (GTN) models to support financial forecasting, pricing scenario planning, and contracting strategy.
- Demonstrated experience designing and implementing payer contracting strategies, including rebate structures and negotiations with pharmacy benefit managers (PBMs), national payer organizations, government payers and regional health plans.
- Strong understanding of U.S. pharmaceutical pricing dynamics, including WAC strategy, payer rebates, contracting frameworks, and market access considerations.
- Experience evaluating government pricing implications including AMP, Best Price, Medicaid rebate exposure, and 340B pricing considerations.
- Experience supporting product launches or late-stage pipeline assets strongly preferred.
- Strong financial modeling and analytical skills with the ability to translate complex pricing and contracting scenarios into strategic recommendations.
- Demonstrated ability to collaborate cross-functionally with Market Access, Finance, Legal, Compliance, Medical Affairs, and Commercial teams.
- Experience supporting pricing governance processes and cross-functional pricing decision frameworks preferred.
- Bachelor's degree required; advanced degree (MBA, MPH, PharmD or similar) preferred.
- Strong leadership, communication, and executive presentation skills.
- Ability to operate effectively in a fast-paced and collaborative biotech environment.
- Willingness to travel as required to support contracting discussions and internal planning
#LI-Remote
The position is eligible for a competitive compensation and benefits package.
Zenas is committed to fair and equitable compensation practices. The base salary pay range for this role is $219,200 to 274,000. Actual compensation packages will depend on various factors, including, but not limited to depth of experience, education, skillset, overall performance and/or location.
Zenas believes in providing a competitive compensation and benefits package to all employees. Our base salary is just one component of Zenas' competitive total rewards strategy that also includes annual performance bonus, equity, full range of benefits and other incentive compensation plans.
Zenas BioPharma is proud to be an equal opportunity employer. We are committed to fostering an environment where diversity is valued. All qualified applicants will receive consideration for employment based on merit, qualifications and the needs of the business.
About Zenas BioPharma
Sourced by ZipRecruiter
Industry
Biotechnology research and development
Company size
11 - 50 Employees
Headquarters location
Waltham, MA, US
Year founded
2021